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STATEMENT: The International Society for Cellular and Gene Therapies (ISCT) and the 
International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular 
vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly 
other cell sources as treatments for COVID-19. Research and trials in this area are 
encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes 
for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting 
regenerative effects, or delivering drugs, pending the generation of appropriate 
manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational 
clinical trial design, and proper regulatory oversight. 
First described in December 2019, the severe acute respiratory syndrome associated with 
coronavirus disease 19 (COVID-19) quickly evolved into a pandemic with severe and 
increasing worldwide morbidity and mortality. Although most infected patients have mild to 
moderate symptoms or are even asymptomatic, older patients or those with existing chronic 
diseases are at greater risk of developing serious complications such as pneumonia or 
multiple organ failures. COVID-19 respiratory infection is marked by dysregulated immune 
responses leading to significant respiratory pathology as well as increased probabilities for 
multi-organ pathologies. While the inflammatory pathways are still being elucidated, notable 
components include increased circulating levels of pro-inflammatory cytokines and other 
mediators including interleukin-6 (IL-6), interleukin-1β (IL-1β), induced protein 10 (IP10) and 
monocyte chemoattractant protein-1 (MCP-1) (Chen et al., 2020; Diao et al., 2020; Yang et 
al., 2020). There are also significant alterations in circulating inflammatory cell populations 
with initial lymphocytosis followed by severe lymphopenia, with increased ratios of helper to 
regulatory T cells (Chen et al., 2020; Diao et al., 2020; Qin et al., 2020). Since dysregulated 
immune responses and the cytokine storm are triggers for development of acute respiratory 
distress syndrome (ARDS), an increasing effort and current clinical trials are focused on 
immune therapeutic approaches such as IL-1 blockade (anakinra), IL-6 receptor blockade 
(tocilizumab) or Janus kinase (JAK) inhibition (Mehta et al., 2020). In parallel, there are a 
rapidly increasing number of cell-based therapy investigations, mostly utilizing mesenchymal 
stromal cells (MSCs) (Khoury et al., 2020a). These are based on supporting pre-clinical data 
for use of MSCs delivered either systemically or intratracheally in pre-clinical models of acute 
lung injuries and on demonstration of safety of systemic MSC administration in recent trials 
for ARDS resulting from other etiologies (Laffey and Matthay, 2017; Matthay et al., 2019).  
Among the cell-based therapy investigations for COVID-19, some registered clinical trials 
aim to utilize extracellular vesicles (EVs) prepared from MSC conditioned media rather than 
the cells themselves. They MSC-EVs will be administered intravenously (ChiCTR2000030484), 
or by inhalation (NCT04276987, ChiCTR2000030261). The rationale for these approaches is 
also based on a relatively small but growing number of investigations in pre-clinical lung 
injury and sepsis models in which MSC-EV preparations were described as safe and 
effective, if not more effective than their parent cells (Mahida et al., 2020; Worthington and 
Hagood, 2020). This approach is further supported by a growing body of literature on the 
therapeutic potential and mechanisms of EVs in a wide range of diseases. This includes 
recent positive results in a steroid-refractory Graft-versus-Host Disease (GvHD) patient 
treated with MSC-EVs, and in a single centre, randomized, placebo-controlled phase II/III 
clinical pilot study on MSC-EV treated patients suffering from chronic kidney disease (CDK) 
(Kordelas et al., 2014; Nassar et al., 2016). 
The mechanisms, by which EVs exert their beneficial effects, as well as their site(s) of action, 
remain incompletely understood. Nonetheless, effects observed in a range of pre-clinical 
non-COVID-19 model systems suggest that they may also have efficacy against COVID-19. 
For example, systemic administration of MSC-EV preparations modulated the immune 
responses including elevated cytokine storms in relevant lung disease models, including 
acute lung injury and sepsis (Liu et al., 2019; Mansouri et al., 2019; Monsel et al., 2015; 
Morrison et al., 2017; Park et al., 2019; Varkouhi et al., 2019; Willis et al., 2018; Zhu et al., 
2014). Noteworthy, in E. coli induced pneumonia mouse models, MSC-EV administration 
was found to enhance phagocytosis of bacteria (Hao et al., 2019; Monsel et al., 2015). In a 
pig model MSC-EVs were shown to attenuate influenza virus-induced acute lung injury, 
amongst others by inhibiting influenza virus replication (Khatri et al., 2018). Disease 
attenuating effects on inflammatory immune responses following MSC-EV administration 
have also been observed in other disease models (Börger et al., 2017). In an ischemic stroke 
model, for example, systemic MSC-EV administration reduced stroke-induced lymphopenia 
and pro-inflammatory immune responses in the brain and periphery, resulting in overall 
improvement of disease symptoms (Doeppner et al., 2015; Wang et al., 2020). These 
preliminary observations support MSC-EV administration as a potential treatment option for 
COVID-19. 
However, the specific scientific rationale for MSC-EV and other EV administration to COVID-
19 patients needs to be better understood and justified. For example, MSC-EVs do not 
necessarily suppress immune responses, but rather modulate them. Specifically, they seem 
to moderate acute immune responses towards regulatory responses, with the latter inducing 
tolerance and restoring homeostasis (Giebel and Hermann, 2019; Zhang et al., 2018; Zhang 
et al., 2014). While tolerance induction in GvHD and other non-infectious diseases may be 
beneficial, it might have severe adverse effects in the presence of replicating pathogens. 
Although influenza and E. coli infections were attenuated in selected models (Hao et al., 
2019; Khatri et al., 2018; Monsel et al., 2015), other viruses and bacteria might conceivably 
expand in uncontrolled manners in induced tolerogenic environments. 
There are a number of additional issues that need to be considered before administering 
MSC-EVs to COVID-19 patients. These include the source of MSC-EVs. MSCs are a 
heterogeneous cell entity that can be obtained from different tissues. Even if derived from the 
same tissues, they may display interindividual and eventually clone specific functional 
differences (Phinney, 2012; Phinney et al., 1999; Radtke et al., 2016; Vogel et al., 2003). 
Indeed, side by side comparison of four MSC-EV preparations harvested from the 
conditioned media of different donor derived bone marrow MSCs demonstrated significant 
variations in cytokine content (Kordelas et al., 2014). Whether this correlates with therapeutic 
potency is not yet clear; however, in the example of the ischemic stroke model, it was 
demonstrated that MSC-EV preparations with comparable particle and protein contents can 
significantly differ in potency. While some preparations effectively suppressed stroke 
symptoms, others failed to exert therapeutic activities (Wang et al., 2020). Furthermore, in an 
acute lung injury model, EVs from young but not from aged MSCs alleviated LPS-induced 
acute lung injury (Huang et al., 2019). 
Potentially, heterogeneity of EV potency due to different sources, preparations, aging, and 
other factors could be resolved by generating immortalized clonal MSC lines that could be 
rigorously tested for EV production and potency (Chen et al., 2011). Still, apart from their 
immunomodulatory capabilities, MSC-EVs apparently also control additional biological 
processes, some with approved therapeutic functions (Arslan et al., 2013), and others that 
might trigger unforeseen side effects. Just recently, it was found that adipose-derived MSC-
EVs had higher thrombogenic activities than bone-marrow-derived MSC-EVs (Chance et al., 
2019; Silachev et al., 2019). Thus, the source of parental cells might increase thrombosis 
risks. Coupled to the finding that activation of complement pathways and an associated 
procoagulant state seem to result in catastrophic microvascular injury syndrome in a 
proportion of severe COVID-19 cases (Magro et al., 2020), MSC-EV administration could 
even be counterproductive in COVID-19.  
To this end, it is imperative that stringent “identity” and “potency” parameters are defined and 
potential side effects addressed before MSC-EV or other EV preparations are released for 
therapeutic applications (Lener et al., 2015; Reiner et al., 2017; Witwer et al., 2019). To date, 
many groups use in-house MSC-EV manufacturing and characterization strategies, mainly 
for preclinical studies (Börger et al., 2017). Protocols fulfilling good manufacturing practice 
(GMP) criteria are sparse, and just a few have been published (Gimona et al., 2017; Pachler 
et al., 2017; Rohde et al., 2019). With those product candidates subsequent studies focusing 
on safety and clinical pharmacology need to be performed. Results of such studies are 
mandatory to provide guidance for adjustment of manufacturing, storage, dosing, and 
administration of EV-based therapeutics in specific target diseases. 
We would like to refer to a recent statement by ISCT on the use of MSCs in COVID-19 
(Khoury et al., 2020b), as many of the same considerations apply to MSC-EVs or other EVs. 
Governmental organizations, healthcare providers, and clinical investigators must take the 
lead by insisting that clinical use of EVs follow appropriate scientific, regulatory and ethical 
guidelines and are approved only after a rigorous review by duly empowered agencies. The 
ethical guidelines produced by the World Health Organization (WHO) are a useful baseline.1 
The urgency of the current outbreak does not justify administration of EVs in rather 
uncontrolled compassionate use settings and does not obviate the need to register clinical 
trials, obtain informed consent from patients or proxies, and otherwise comply with good 
clinical practice (GCP). In particular, even limited compassionate use should employ well-
characterized MSC-EV preparations produced through strict GMP conditions under the 
oversight of the relevant national regulatory entity. Additional outbreak-specific measures 
may be needed, including establishment of simplified clinical protocols for hospitalized 
patients, such as the WHO COVID-19 core protocol, minimizing risks to trial integrity,2 
changing logistics of trial participant visits (e.g. implementation of remote assessments), and 
protocol changes for the sake of hazard minimization that may need to be implemented and 
reported, in Europe, to the Institute for Research in Biomedicine (IRB) Barcelona after the 
fact. Certainly, regulatory flexibility and support is helpful to foster developments, such as the 
US Food and Drug Administration (FDA) special emergency program for possible therapies, 
the Coronavirus Treatment Acceleration Program (CTAP),3 the European Medicines Agency 
(EMA) COVID-19 pandemic Task Force (COVID-ETF) activities,4 the EMA guidance for 
medicine developers and companies on COVID-195 and the guidelines for clinical trials 
published by an EMA coordinated group6, or the Medicines and Healthcare products 
                                               
1 Organisation WH. Guidance for managing ethical issues in infectious disease outbreaks. World Heal Organ 
2016:62. 
2 FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic Guidance for 
Industry, Investigators, and Institutional Review Boards. 2020. 
3 Coronavirus Treatment Acceleration Program (CTAP) | FDA n.d. https://www.fda.gov/drugs/coronavirus-covid-
19-drugs/coronavirus-treatment-acceleration-program-ctap (accessed April 1, 2020). 
4 COVID-19 EMA pandemic Task Force (COVID-ETF): "to help EU Member States and the European 
Commission to take quick and coordinated regulatory action on the development, authorisation and safety 






Regulatory Agency (MHRA),7 respectively. Most or all of the considerations covered for cell-
based therapies are also applicable to EV investigations. 
In conclusion, to mitigate the risk of potential of life-threatening side effects, ISCT and ISEV 
strongly urge that the potential benefits and risks in the use of MSC-EVs for COVID-19 be 
weighed carefully against available pre-clinical data in relevant animal models and clinical 
data from relevant MSC clinical trials, and that any use of EVs be carefully evaluated through 
rational clinical trial design, employing well-characterized EV preparations produced under 
strict GMP conditions and under the proper regulatory oversight. 
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